dapagliflozin + Placebo
ApprovedCompleted 2 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Atrial Fibrillation
Conditions
Atrial Fibrillation
Trial Timeline
Jul 27, 2021 → Jun 30, 2023
NCT ID
NCT04792190About dapagliflozin + Placebo
dapagliflozin + Placebo is a approved stage product being developed by AstraZeneca for Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT04792190. Target conditions include Atrial Fibrillation.
What happened to similar drugs?
20 of 20 similar drugs in Atrial Fibrillation were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04792190 | Approved | Completed |
| NCT04869124 | Approved | Completed |
| NCT04564742 | Phase 3 | Completed |
| NCT04363697 | Approved | Completed |
| NCT04475042 | Phase 2 | UNKNOWN |
| NCT02981966 | Approved | Completed |
| NCT03619213 | Phase 3 | Completed |
| NCT03387683 | Approved | Completed |
| NCT02956811 | Approved | Completed |
| NCT03036124 | Phase 3 | Completed |
| NCT03036150 | Phase 3 | Completed |
| NCT02796170 | Approved | Completed |
| NCT02520518 | Phase 2 | Terminated |
| NCT02459353 | Approved | Completed |
| NCT02371187 | Phase 2 | Completed |
| NCT02426541 | Approved | Completed |
| NCT01392677 | Phase 3 | Completed |
| NCT01042977 | Phase 3 | Completed |
| NCT01031680 | Phase 3 | Completed |
| NCT00984867 | Phase 3 | Completed |
Competing Products
20 competing products in Atrial Fibrillation